Pfizer's RSV Vaccine Abrysvo Shows Positive Response After Single Dose
By Michael Susin
Pfizer on Monday said that top-line data from a late-stage study regarding its vaccine for respiratory syncytial virus, or RSV, showed that the treatment generated strong neutralizing responses after a single dose in adults.
The company said the Phase 3 study evaluating two doses of Abrysvo versus placebo in adults with immunocompromising conditions who are at risk of developing severe RSV-associated lower respiratory tract disease, showed that a single dose of the drug generated strong neutralizing response across all cohorts and age groups. The drug was also well tolerated during the trial, showing a safety profile consistent with other studies of the vaccine.
Pfizer said it plans to share these findings at an upcoming scientific conference and to submit these data to the regulatory agencies for review.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
August 12, 2024 07:32 ET (11:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks